Fancois Xavier Frapaise
Biosimilars Consultant Paris, France
Biography
Francois-Xavier Frapaise, M.D has over 30 years of international drug development experience at major pharmaceutical companies including Sanofi, Bayer, Boehringer, Merck, and Abbott; he has held multiple C- level positions (CSO, CMO, CEO) in different pharmacies in the US and Europe. He has extensive experience of biosimilars development (Boehringer-Ingelheim, Pfenex, Merck KGaA) and is currently heading a biosimilar consulting company. He has been the CSO and SVP of Optimer, has served as the CEO of Asphelia Pharmaceuticals, Inc. VP R&D and corporate officer of TAP, CMO of Ocera Therapeutics, VP of Scientific Affairs at Abbott International, Head of Medical Affairs at Bayer Europe, Medical Director at Bayer France, VP of R&D at Delagrange, Head of Anti-thrombotics Strategic Marketing at Sanofi, Medical Director at Choay. He holds an M.D. degree from Faculté of Medecine and holds an academic position at the Thrombosis Research Center at the Loyola Medical Center in Maywood (IL).
Abstract
Abstract : The end of clinical trials in biosimilars development